Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes

Rury R. Holman; Harald Sourij; Robert M. Califf

doi:10.1016/s0140-6736(14)60794-7

Keywords

MedicineDiabetes mellitusType 2 diabetesClinical trialDiseaseEmpagliflozinIntensive care medicineRandomized controlled trialWeight lossInternal medicineObesityEndocrinology

Affiliated Institutions

Related Publications

Improvement in Cardiovascular Outcomes With Empagliflozin Is Independent of Glycemic Control

Silvio E. Inzucchi , Mikhail Kosiborod , David Fitchett +5 more

Key Words: blood glucose ◼ sodiumglucose transporter 2 ◼ treatment outcome ◼ type 2 diabetes mellitus C ardiovascular disease (CVD) is the leading cause of death in type 2 diabe...

2018 Circulation 156 citations

Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON

Muh Geot Wong , Vlado Perkovic , John Chalmers +15 more

OBJECTIVE The Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) trial reported that intensive glucose control prevents end-stage...

2016 Diabetes Care 226 citations

Sodium Glucose Cotransporter-2 Inhibition in Heart Failure

Yuliya Lytvyn , Petter Bjornstad , Jacob A. Udell +2 more

Despite current established therapy, heart failure (HF) remains a leading cause of hospitalization and mortality worldwide. Novel therapeutic targets are therefore needed to imp...

2017 Circulation 445 citations

Effects of Intensive Glucose Lowering in Type 2 Diabetes

Hertzel C. Gerstein , Michael E. Miller , Robert P. Byington +10 more

As compared with standard therapy, the use of intensive therapy to target normal glycated hemoglobin levels for 3.5 years increased mortality and did not significantly reduce ma...

2008 New England Journal of Medicine 7743 citations

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

Bruce Neal , Vlado Perkovic , Kenneth W. Mahaffey +7 more

Background Canagliflozin is a sodium-glucose cotransporter 2 inhibitor that reduces glycemia as well as blood pressure, body weight, and albuminuria in people with diabetes. We ...

2017 New England Journal of Medicine 7382 citations

Publication Info

Year: 2014
Type: review
Volume: 383
Issue: 9933
Pages: 2008-2017
Citations: 228
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

228

OpenAlex

Cite This

APA Style

                            
                                    Rury R. Holman, 
                                
                                    Harald Sourij, 
                                
                                    Robert M. Califf
                                
                            (2014). 
                            Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes. 
                            The Lancet
                            , 383
                            (9933)
                            , 2008-2017.
                            https://doi.org/10.1016/s0140-6736(14)60794-7

Identifiers

DOI: 10.1016/s0140-6736(14)60794-7